Universal newborn screening for permanent hearing impairment
Submitting Institution
University of SouthamptonUnit of Assessment
Clinical MedicineSummary Impact Type
PoliticalResearch Subject Area(s)
Medical and Health Sciences: Public Health and Health Services
Summary of the impact
Permanent childhood hearing impairment (PCHI) is common and adversely
affects language acquisition. Early identification enables effective early
interventions including hearing aids and cochlear implants. Research at
Southampton was central to the case accepted by policymakers in the UK,
USA and across several continents to recommend universal newborn screening
(UNS) for PCHI. From 2008-13 more than three million babies in the UK were
screened and over 5,000 cases of PCHI were identified with benefit to
family functioning, literacy, academic achievement, social-emotional
well-being, employment, wider society and the UK economy.
Underpinning research
PCHI can have adverse effects on a child's neuronal development, language
acquisition and educational outcomes. If PCHI is detected at an early age,
children can be provided with educational support, hearing aids and
cochlear implants. Prior to 2001, the standard test for PCHI in the UK was
the health visitor distraction test (HVDT). Health workers attempted to
distract babies with a noise and then assess their reactions. This method
posed two significant problems: the subjectivity of the test and the
relatively late developmental age — seven months — at which it can be
carried out.
A programme of work headed by Colin Kennedy (1988-date, Professor of
Neurology and Paediatrics since 2006) has led research demonstrating that
tests based on transient evoked otoacoustic emissions (TEOAEs) - low level
sounds detectable by a microphone in the ear canal of a normally
functioning cochlea - combined with automated auditory brain stem response
testing in cases whose TEOAEs are undetectable, are effective as a UNS for
bilateral (PCHI >40 decibels Hearing Level (dB HL) over four sound
frequencies) [3.1, 3.2]. This degree of PCHI occurs in more than 1
in 1000 babies.
A population-based trial across Wessex in over 50,000 newborns showed
that UNS increased the odds of referral of cases of bilateral PCHI >40
dB HL prior to age six months 19 fold (95% CI 3.2 to 111.0) [3.1].
Over an eight-year period to 2003, a follow-up study of the birth cohort
enrolled in the Wessex Trial allowed the identification of all true cases
of PCHI, including UNS false negatives and cases of progressive PCHI [3.3].
UNS more than doubled the proportion of all true cases of PCHI that were
referred before age six months from 31% to 74% [3.3].
The children with PCHI were further studied at age 7-9 years with an
additional cohort aged 6-10 years from four districts in Greater London [3.4-3.6],
including the only two districts in the UK providing UNS. In this sample
(and also in subgroup analysis of the Wessex cohort), UNS was associated
with higher adjusted group mean z scores for receptive language as
compared with nonverbal ability (difference, 0.60; 95% CI 0.07 to 1.13)
and for reading (difference 0.39; 95% CI 0.02 to 0.76) and with £2213
lower educational costs in a 12-month period [3.4-3.6].
The steering committees for these and collaborative studies and its
2009-13 continuation comprised predominantly of members of the University
of Southampton's Faculty of Medicine (M Campbell; C Kennedy; L Kim; D
McCann; J Peacock; H Pimperton; S Worsfold) but also included members from
other Faculties in the University of Southampton (Institute of Sound and
Vibration Research UoA15; School of Psychology UoA4; Wessex Institute
UoA1,2); the MRC Institute of Hearing Research; Whipps Cross Hospital;
NPEU, Oxford; School of Education, Birmingham; UCL Developmental Sciences.
The Wessex Trial's experimental design and health economic analysis of
benefit [3.6] enabled a demonstration of benefit of UNS to
language at primary school age in a population-based study that remains
unique in the field. It made the argument for UNS rather than targeted
screening and was crucial to decisions by the UK national screening
committee and the US Preventative Service Task Force to recommend
implementation of UNS nationally and federally respectively.
In a further follow-up study of the same cohort, now of secondary school
age (13-18 years), data collection was completed in April 2013. This will
provide unique information on the longer-term impact of UNS on reading,
language, socialisation and health economic benefit in teenage years.
References to the research
Authors from the Faculty of Medicine of the University of Southampton are
in italics.
3.1 Wessex Universal Neonatal Hearing Screening Trial Group.
Controlled trial of universal neonatal screening for early
identification of permanent childhood hearing impairment. The Lancet
1998, 352:1957-1964. The writing committee was comprised of
Kennedy CR, Kimm L, Campbell M, Cafarelli-Dees D (ISVR of The UoS),
Thornton ARD (MRC Southampton Hearing Research Unit).
3.2 Kennedy CR, Kimm L, Thornton R, Davis A. False
positives in universal neonatal screening for permanent childhood hearing
impairment. The Lancet 2000; 356:1903-04.
3.3 Kennedy C, McCann D, Campbell MJ, Kimm L, Thornton R.
Universal newborn screening for permanent childhood hearing impairment: an
8-year follow-up of a controlled trial The Lancet 2005;
366:660-662.
3.4 Kennedy CR, McCann D, Campbell MJ, Law C, Mullee M,
Petrou S, Watkin P, Worsfold S, Yuen HM,
Stevenson J. Language ability after early detection of permanent childhood
hearing impairment. New England Journal of Medicine 2006;
354:2131-41.
3.5 McCann DC, Worsfold S, Campbell MJ, Law CM, Mullee
M, Petrou S, Stevenson J, Watkin P, Yuen HM, Kennedy CR.
Reading and communication skills after early life detection of permanent
hearing impairment. Arch Dis Child 2009; 94:293-297.
3.6 Schroeder L, Petrou S, McCann D, Law C, Watkin PM, Worsfold
S, Yuen HM, Kennedy CR. The economic costs of congenital bilateral
permanent childhood hearing impairment. Pediatrics 2006; 117:1101-12.
Grants
Dates |
Award
Holder |
Funding
Body |
Title |
Value |
1992-1996 |
Kennedy |
Wellcome Trust |
Controlled trial of UNS for PCHI; |
£407,472 |
2001-2005 |
Kennedy |
Wellcome Trust |
Effect of early treatment of
PCHI on outcome at 8 to 9 years |
£371,000 |
2010-2013 |
Kennedy |
Wellcome Trust |
Effect of early intervention
for PCHI on outcome at
secondary school age |
£362,323 |
Details of the impact
The results of the Wessex Trial were used extensively in the key 1997
document commissioned by the Department of Health to review the relevant
data and make recommendations on a screening programme. This review, which
led directly to the implementation of UNS now in place throughout the UK,
singled out the Wessex trial for its size, quality, and design; the review
also specifically recommends that providers build on the experience of
this trial. In the history of the NHS Neonatal Hearing Screening Project,
written by the Medical Research Council and posted on the current
"Achievements & Impact" page of its website, it is one of only two
clinical trials cited [5.1].
The growth in the use of evidence-based medicine has led to systematic
reviews of trials becoming increasing influential in formulating health
policy and the Wessex trial is one of only two trials worldwide rated as
"good" following a major systematic review of the evidence in 2001. The
follow- up study of the effect of UNS on language is also one of only two
trials rated as "good" in the 2008 update of that systematic review [5.2]
and, of these two, only the Wessex Trial evaluated the benefit of
universal, as opposed to targeted, newborn screening.
Following the Hearing Outcomes Project that documented outcomes following
the Wessex Trial, Kennedy gave evidence to the US Preventative Services
Task Force (USPSTF) in October 2006 both on data already published and
also on data, subsequently published in 2009, documenting benefits to
reading ability in the same sample [3.6]. This played a
significant role in the USPSTF systematic review [5.2] that
focused heavily on the benefits to language reported by Kennedy et al in
The New England Journal of Medicine [3.4] and in the change in the
linked USPSTF recommendation on UNS from `Insufficient Evidence' in 2001
to `Recommend' in 2008 [5.3]. The fact that the report by
Schroeder et al [3.6] of a reduction in the cost of educational
special support associated with early intervention and other economic
impact on families and society increased the influence of Southampton's
work on health policy, both in the UK and overseas, is also clear from
subsequent reviews published in 2012 [5.4, 5.5].
The impact of UNS for PCHI dominates all newborn screening for any
disorder: the number of cases of PCHI detected by UNS in the USA in 2009
was estimated to be 5,073 accounting for 43.3% of all detected cases of
the 29 conditions for which newborn screening is recommended [5.6].
The impact on patients in the UK began in 2001 as the Neonatal Hearing
Screening Programme (NHSP) was rolled out, and continues to the present
day. PCHI affects over one in 1400 babies born in England each year. In a
typical week in 2012, 13,290 babies were screened in England, with 336 of
these being referred for further audiological testing, and 27 identified
as having PCHI [5.7]. Thus from 2008 to 2013, it is estimated that
over five million babies in England will have been screened [5.8],
and over 8,000 identified with PCHI. The consequences of early treatment
of PCHI on the development of neural pathways and language, family
functioning, literacy, academic achievement, social-emotional well-being
and employment [5.4] impact not only on the child and their
family, but also financially on the wider society and the UK economy.
In the annual report on the NHS NHSP for 2008-09, Susan Daniels, Chief
Executive of the National Deaf Children's Society [5.9] said this
about the universal screening program: "Detecting deafness as soon in life
as possible gives children the best chance of fulfb01lling their
potential. It enables families to access early intervention and support
services earlier, offers them greater choices and has a proven impact on
the development of language and communication skills, as well as
contributing to the closure of the attainment gap between deaf children
and their peers."
Then Secretary of State for Health, Andrew Lansley, backed the program by
saying in 2012: "The NHS Newborn Hearing Screening Programme ... allows
babies with hearing problems to receive the support they need earlier to
give them the best possible start in life." [5.10]
The introduction of the NHS NHSP has led to a dramatic reduction in the
median age of identification of PCHI. In a respected 2005 review [5.4],
the median age at identification was shown to fall from 60 to 10 weeks on
introduction of the NHSP. The reduction for the upper quartile age was
even more dramatic: from 210 to 25 weeks. These represent substantial
improvements in the prospects for these babies. These changes have led to
similarly dramatic reductions in the age of clinical interventions such as
the fitting of hearing aids or cochlear implantation.
Similar benefits are also occurring in wider Europe, North America and
other continents with associated improvements in quality of life and
financial savings for society [5.3, 5.5, 5.11]. For example, by
2010 UNHS had been implemented in 20 of the 32 provinces in China, where
115,000 children under the age of seven suffer from severe-to-profound
deafness and where 30,000 babies are born each year with a hearing
impairment. In 2009, the Chinese government set up a project to offer
cochlear implants to 1,500 children aged 1-5 years over the next three
years. By 2011, the government had agreed to fund implants for an
additional 17,000 children over four years [5.11].
In summary, the widespread introduction of UNS programmes, based on
pivotal research led by Kennedy in Southampton has had an impact on
improving the quality of life of many thousands of babies and their
families in the UK and Worldwide.
Sources to corroborate the impact
5.1 http://www.mrc.ac.uk/Achievementsimpact/Storiesofimpact/Hearingscreen/index.htm
(accessed 25/04/2013)
5.2 Nelson HD, Bougatsos C, Nygren P. Universal newborn hearing
screening: systematic review to update the 2001 US Preventive Services
Task Force Recommendation. Pediatrics 2008; 122:e266-76.
5.3 US Preventative Services Task Force. Universal screening for
hearing loss in newborns: US Preventive Services Task Force recommendation
statement. Pediatrics 2008; 122:143-148 [RECOMMENDATION. Screen
for hearing loss in all newborn infants (B recommendation).]
5.4 Pimperton H, Kennedy C. The impact of early identification of
permanent childhood hearing impairment on speech and language outcomes. Archives
of Disease in Childhood 2012; 97:648-653.
5.5 Olusanya BO. Neonatal hearing screening and intervention in
resource-limited settings: an overview. Archives of Disease in
Childhood 2012; 97: 654-59.
5.6 Howell RR, Terry S, Tait VF et al. CDC grand rounds: newborn
screening and improved outcomes. MMWR 2012; 61 (21) 390-93.
5.7 NHS NHSP: http://hearing.screening.nhs.uk/statistics
(accessed 23/05/2013). The NHS NHSP is also a beneficiary of this work.
5.8 National Deaf Children's Society website http://www.ndcs.org.uk/family_support/audiology/newborn_hearing_screening/
5.9 2008-09 annual report: http://goo.gl/EMiW9c
5.10 Comment by former Secretary of State for Health Andrew
Lansley http://hearing.screening.nhs.uk/5million
5.11 Liang Q, Mason B. Enter the dragon — China's journey to the
hearing world. Cochlear Implant International 2013; Suppl
1:526-31.